XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Acquisitions | 3 Months Ended
--- | ---
Mar. 31, 2018
Business Combinations [Abstract] |
Acquisitions | ACQUISITIONS We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. In the three months 2018 and 2017 cash paid for acquisitions, net of cash acquired, was $704 and $9. In February 2018 we completed the acquisition of Entellus Medical, Inc. (Entellus) for $24.00 per share, or an aggregate purchase price of $697, net of cash acquired. Entellus is focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of various ear, nose and throat (ENT) disease states. Entellus is part of the Neurotechnology business within Neurotechnology and Spine. Goodwill attributable to the acquisition of Entellus is not deductible for tax purposes. In September 2017 we completed the acquisition of NOVADAQ Technologies Inc. (NOVADAQ) for an aggregate purchase price of $674, net of cash acquired. NOVADAQ is a leading developer of fluorescence imaging technology that provides surgeons with visualization of blood flow in vessels and related tissue perfusion in cardiac, cardiovascular, gastrointestinal, plastic, microsurgical, and reconstructive procedures. NOVADAQ is part of the Endoscopy business within the MedSurg segment. Goodwill attributable to the acquisition of NOVADAQ is not deductible for tax purposes. Purchase price allocations for Entellus and NOVADAQ were based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period.
Purchase Price Allocation of Acquired Net Assets
| 2018 |  | 2017
| Entellus |  | NOVADAQ
Purchase price, net of cash acquired | $ | 697 |  |  | $ | 674 |
Tangible assets: |  |  |
Accounts receivable | 17 |  |  | 11 |
Inventory | 14 |  |  | 39 |
Other assets | 66 |  |  | 9 |
Contingent consideration | (78 | ) |  | — |
Other liabilities | (92 | ) |  | (59 | )
Intangible assets: |  |  |
Customer relationship | 33 |  |  | 18 |
Trade name | — |  |  | 1 |
Developed technology and patents | 256 |  |  | 133 |
Goodwill | 481 |  |  | 522 |
| $ | 697 |  |  | $ | 674 |
Weighted-average life of intangible assets | 16 |  |  | 14 |
Estimated Amortization Expense
Remainder of 2018 | 2019 | 2020 | 2021 | 2022
$ | 287 |  | $ | 370 |  | $ | 345 |  | $ | 333 |  | $ | 327 |

X
- Definition The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable). + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_BusinessCombinationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_BusinessCombinationsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration